This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Campus
  1. Article
  2. Source: Campus Sanofi
  3. 23 Oct 2023

T1DM - Meta-Analysis

Author: Sanofi

Editorial Team

                   

Prescribing Information Toujeo (insulin glargine 300 units/mL)
Prescribing Information Lantus (insulin glargine 100 units/mL)

toujeo logo
Sanofi is here to support you and your patients.

Ask us your questions about our products, patient materials or organising a meeting.

T1-Meta Analysis

Download this clinical summary to read about the benefits of Toujeo® in this post-hoc meta-analysis of three Edition 6 month, phase III, randomised trials. The study aimed to explore the risk of hypoglycaemia with Toujeo® vs insulin glargine 100U/mL in a broad pool of people with T1DM including children over the age of 6.

SEE MORE FROM SCIENCE

Toujeo

Toujeo® is indicated as treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years. 

Patient Website

Find resources and support for your patients on Toujeo®. Help patients understand the basics of living and staying well with diabetes and how to have a positive start and experience with the medication prescribed to them.

MAT-XU-2205629 (v5.0) Date of Preparation: October 2023